We have observed
8 EP applications
has served for within the last five+ years.
(We consider all applications which have an EP A1 or A2 publication dated after June 14, 2013).
Please note, that we only count EP applications,
in which the name of the patent attorney is explicitly mentioned as representative.
These EP applications are:
Antitumoral combination comprising cabazitaxel and cisplatin
ANTITUMORAL COMBINATION COMPRISING CABAZITAXEL AND CISPLATIN
Anhydrous crystalline form of dimethoxy docetaxel and methods for preparing it
Compositions and methods for analyzing histidine phosphorylation
METHODS FOR TREATING CANCER USING PI3K INHIBITOR AND MEK INHIBITOR
TABLET FORMULATION OF A PHOSPHATIDYLINOSITOL 3-KINASE INHIBITOR
CABAZITAXEL AND ITS USE FOR TREATING CANCER